Diana Abdueva, Aqtual CEO

Aq­tu­al rais­es $16M for liq­uid biop­sy test for rheuma­toid arthri­tis based on cell-free DNA plat­form

Aq­tu­al emerged from stealth on Tues­day with $16 mil­lion in Se­ries A funds and plans to use its cell-free DNA plat­form to de­vel­op a blood test for pa­tients with rheuma­toid arthri­tis in the hopes of more quick­ly get­ting to the best treat­ment.

Ac­cord­ing to the Cal­i­for­nia-based pre­ci­sion med­i­cine com­pa­ny, there are more than 20 avail­able drugs in six drug class­es for rheuma­toid arthri­tis — and most pa­tients try two or three drugs be­fore find­ing one that works best.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.